• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5081001)   Today's Articles (1092)
For: Booth CM, Sengar M, Goodman A, Wilson B, Aggarwal A, Berry S, Collingridge D, Denburg A, Eisenhauer EA, Ginsburg O, Goldstein D, Gunasekera S, Hammad N, Honda K, Jackson C, Karikios D, Knopf K, Koven R, Marini BL, Maskens D, Moraes FY, Mohyuddin GR, Poudyal BS, Pramesh CS, Roitberg F, Rubagumya F, Schott S, Sirohi B, Soto-Perez-de-Celis E, Sullivan R, Tannock IF, Trapani D, Tregear M, van der Graaf W, Vanderpuye V, Gyawali B. Common Sense Oncology: outcomes that matter. Lancet Oncol 2023;24:833-835. [PMID: 37467768 DOI: 10.1016/s1470-2045(23)00319-4] [Citation(s) in RCA: 52] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 06/26/2023] [Accepted: 06/27/2023] [Indexed: 07/21/2023]
Number Cited by Other Article(s)
1
Lee KL, Eniu A, Booth CM, MacDonald M, Chino F. Financial Toxicity and Breast Cancer: Why Does It Matter, Who Is at Risk, and How Do We Intervene? Am Soc Clin Oncol Educ Book 2025;45:e473450. [PMID: 40315376 DOI: 10.1200/edbk-25-473450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/04/2025]
2
Reiss KA, Soares KC, Torphy RJ, Gyawali B. Treatment Innovations in Pancreatic Cancer: Putting Patient Priorities First. Am Soc Clin Oncol Educ Book 2025;45:e473204. [PMID: 40173379 DOI: 10.1200/edbk-25-473204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2025]
3
Eisenhauer EA, Abdihamid O, Booth CM, Cherny N, Fojo AT, Gyawali B, Marini BL, Mohyuddin GR, Pe M, Pond GR, Soto-Perez-de-Celis E, Tannock IF, Trapani D, Tregear M, van der Graaf WTA, Wilson BE. Guidance for discussants of randomized cancer trials at major meetings. Eur J Cancer 2025;220:115357. [PMID: 40117861 DOI: 10.1016/j.ejca.2025.115357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2025] [Accepted: 03/05/2025] [Indexed: 03/23/2025]
4
Portik D, Lacombe D, Faivre-Finn C, Achard V, Andratschke N, Correia D, Spalek M, Guckenberger M, Ost P, Ehret F. The 2024 State of Science report from the European Organisation for Research and Treatment of Cancer's Radiation Oncology Scientific Council. Eur J Cancer 2025;220:115334. [PMID: 40127505 DOI: 10.1016/j.ejca.2025.115334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2025] [Accepted: 02/27/2025] [Indexed: 03/26/2025]
5
Milrod CJ, Rubin L, Martinez B, Ollila TA, Olszewski AJ, Pelcovits A. Quality-of-life endpoints collection, reporting, and framing in randomised trials of indolent lymphomas: a systematic review. Lancet Haematol 2025;12:e312-e317. [PMID: 40175003 DOI: 10.1016/s2352-3026(25)00032-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2024] [Revised: 01/24/2025] [Accepted: 02/03/2025] [Indexed: 04/04/2025]
6
Jassal SV, Loon IV. Redesigning peritoneal dialysis care: The introduction of frailty-informed pathways. Perit Dial Int 2025;45:70-73. [PMID: 40013751 DOI: 10.1177/08968608241304272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/28/2025]  Open
7
Donia M, Jespersen H, Jalving M, Lee R, Eriksson H, Hoeller C, Hernberg M, Gavrilova I, Kandolf L, Liszkay G, Helgadottir H, Zhukavets A, Pianova D, Marquez-Rodas I, Neyns B, Westgeest H, Pourmir I, Sobczuk P, Ellebaek E, Amaral T. Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028. ESMO Open 2025;10:104295. [PMID: 39954389 PMCID: PMC11872484 DOI: 10.1016/j.esmoop.2025.104295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2024] [Revised: 01/21/2025] [Accepted: 01/21/2025] [Indexed: 02/17/2025]  Open
8
Aaron DG, Robertson CT, King LP, Sage WM. A New Legal Standard for Medical Malpractice. JAMA 2025:2830847. [PMID: 40009364 DOI: 10.1001/jama.2025.0097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/27/2025]
9
Williams N, Russell H, Bradhurst B. Exploring clinical trials awareness, information access and participation amongst Australians with ovarian cancer: a qualitative study. Support Care Cancer 2025;33:176. [PMID: 39934363 PMCID: PMC11814028 DOI: 10.1007/s00520-025-09221-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2024] [Accepted: 01/29/2025] [Indexed: 02/13/2025]
10
Gyawali B, Eisenhauer EA, van der Graaf W, Booth CM, Cherny NI, Goodman AM, Koven R, Pe ML, Marini BL, Mohyuddin GR, Pond GR, Sengar M, Soto-Perez-de-Celis E, Trapani D, Tregear M, Wilson BE, Tannock IF. Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials. Lancet Oncol 2025;26:e80-e89. [PMID: 39914429 DOI: 10.1016/s1470-2045(24)00451-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2024] [Revised: 08/01/2024] [Accepted: 08/13/2024] [Indexed: 05/07/2025]
11
Battaiotto E, d'Ambrosio S, Trapani D, Curigliano G. Metronomic Chemotherapy in Breast Cancer as a Strategy to Deliver More Sustainable and Less Toxic Treatments: Time to Debunk the Myth? Clin Breast Cancer 2025;25:85-95.e18. [PMID: 39627044 DOI: 10.1016/j.clbc.2024.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2024] [Accepted: 11/02/2024] [Indexed: 01/28/2025]
12
Rangoonwala HI, Morgan JS, Melly E, Siika A, Loehrer PJ, Busakhala N. Global Equity in Clinical Trials: A Pragmatic Approach. JCO Glob Oncol 2025;11:e2400557. [PMID: 39836944 DOI: 10.1200/go-24-00557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2024] [Accepted: 12/11/2024] [Indexed: 01/23/2025]  Open
13
Ul Haq MZ, Heredia C, Buadu A, Rizvi A, Workentin A, Persaud N. Changes in essential cancer medicines and association with cancer outcomes: an observational study of 158 countries. BMC Cancer 2024;24:1526. [PMID: 39696026 DOI: 10.1186/s12885-024-13247-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2024] [Accepted: 11/25/2024] [Indexed: 12/20/2024]  Open
14
Trapani D, Bhoo-Pathy N. The trade-off between accelerated cancer drug approvals and patient preferences. Lancet Oncol 2024;25:1516-1517. [PMID: 39571595 DOI: 10.1016/s1470-2045(24)00654-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2024] [Revised: 10/31/2024] [Accepted: 11/04/2024] [Indexed: 12/07/2024]
15
Lacombe D, Borges FC. Do regulations and policies undermine the social value of independent academic research? Eur J Cancer 2024;213:115076. [PMID: 39455354 DOI: 10.1016/j.ejca.2024.115076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2024] [Revised: 10/17/2024] [Accepted: 10/17/2024] [Indexed: 10/28/2024]
16
Forrest R, Lagarde M, Aggarwal A, Naci H. Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. Lancet Oncol 2024;25:1635-1643. [PMID: 39571597 DOI: 10.1016/s1470-2045(24)00596-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2024] [Revised: 09/28/2024] [Accepted: 10/16/2024] [Indexed: 12/07/2024]
17
Verduzco-Aguirre H, Wilson BE. Balancing clinical benefit and social value: challenges in HTA assessments. Lancet Oncol 2024;25:1518-1519. [PMID: 39637884 DOI: 10.1016/s1470-2045(24)00557-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2024] [Accepted: 09/24/2024] [Indexed: 12/07/2024]
18
Sherry AD, Lin TA, McCaw ZR, Beck EJ, Kouzy R, Jaoude JA, Passy AH, Miller AM, Kupferman GS, Fuller CD, Thomas CR, Koay EJ, Tang C, Msaouel P, Ludmir EB. Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials. Int J Cancer 2024;155:1939-1943. [PMID: 39138841 PMCID: PMC11449668 DOI: 10.1002/ijc.35129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2024] [Revised: 06/07/2024] [Accepted: 07/01/2024] [Indexed: 08/15/2024]
19
Zhu Z, Pan X. Cancer care equality: for the interests of patients with cancer. ESMO Open 2024;9:103971. [PMID: 39500141 PMCID: PMC11570511 DOI: 10.1016/j.esmoop.2024.103971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2024] [Revised: 09/28/2024] [Accepted: 10/01/2024] [Indexed: 11/21/2024]  Open
20
Michaeli JC, Michaeli T, Trapani D, Albers S, Dannehl D, Würstlein R, Michaeli DT. Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price. Breast Cancer 2024;31:1144-1155. [PMID: 39320645 PMCID: PMC11489271 DOI: 10.1007/s12282-024-01634-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2024] [Accepted: 09/15/2024] [Indexed: 09/26/2024]
21
Banerjee S, Booth CM, Bruera E, Büchler MW, Drilon A, Fry TJ, Ghobrial IM, Gianni L, Jain RK, Kroemer G, Llovet JM, Long GV, Pantel K, Pritchard-Jones K, Scher HI, Tabernero J, Weichselbaum RR, Weller M, Wu YL. Two decades of advances in clinical oncology - lessons learned and future directions. Nat Rev Clin Oncol 2024;21:771-780. [PMID: 39354161 DOI: 10.1038/s41571-024-00945-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/10/2024] [Indexed: 10/03/2024]
22
Mainou M, Tsapa K, Michailidis T, Malandris K, Karagiannis T, Avgerinos I, Liakos A, Papaioannou M, Terpos E, Prasad V, Tsapas A. Outcomes in randomized controlled trials of therapeutic interventions for multiple myeloma: A systematic review. Crit Rev Oncol Hematol 2024;204:104529. [PMID: 39368634 DOI: 10.1016/j.critrevonc.2024.104529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2024] [Revised: 09/30/2024] [Accepted: 10/01/2024] [Indexed: 10/07/2024]  Open
23
Aranda-Gutierrez A, Soto-Perez-de-Celis E. The Disconnect between Clinical Guidelines and Reality: The Case of Trastuzumab. Cancer Epidemiol Biomarkers Prev 2024;33:1259-1260. [PMID: 39354816 DOI: 10.1158/1055-9965.epi-24-0906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2024] [Revised: 07/11/2024] [Accepted: 07/18/2024] [Indexed: 10/03/2024]  Open
24
Sun D, Macedonia C, Chen Z, Chandrasekaran S, Najarian K, Zhou S, Cernak T, Ellingrod VL, Jagadish HV, Marini B, Pai M, Violi A, Rech JC, Wang S, Li Y, Athey B, Omenn GS. Can Machine Learning Overcome the 95% Failure Rate and Reality that Only 30% of Approved Cancer Drugs Meaningfully Extend Patient Survival? J Med Chem 2024;67:16035-16055. [PMID: 39253942 DOI: 10.1021/acs.jmedchem.4c01684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/11/2024]
25
Pokorny AMJ. (Un)common sense in oncology. Drug Ther Bull 2024;62:146. [PMID: 39242152 DOI: 10.1136/dtb.2024.000043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/09/2024]
26
Sorigue M. Moving forward with [18F]FDG PET/CT in low tumor burden follicular lymphoma. Eur J Radiol 2024;181:111747. [PMID: 39332353 DOI: 10.1016/j.ejrad.2024.111747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2024] [Accepted: 09/17/2024] [Indexed: 09/29/2024]
27
Bührer E, Kicinski M, Mandala M, Pe M, Long GV, Atkinson V, Blank CU, Haydon A, Dalle S, Khattak A, Carlino MS, Meshcheryakov A, Sandhu S, Puig S, Schadendorf D, Jamal R, Rutkowski P, van den Eertwegh AJM, Coens C, Grebennik D, Krepler C, Robert C, Eggermont AMM. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 2024;25:1202-1212. [PMID: 39146951 DOI: 10.1016/s1470-2045(24)00338-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2024] [Revised: 06/05/2024] [Accepted: 06/06/2024] [Indexed: 08/17/2024]
28
Mac Eochagain C, Power R, Sam C, Gonzalez-Senac NM, Walsh D, Roy M, Battisti NML. Inclusion, characteristics, and reporting of older adults in FDA registration studies of immunotherapy, 2018-2022. J Immunother Cancer 2024;12:e009258. [PMID: 39209450 PMCID: PMC11367347 DOI: 10.1136/jitc-2024-009258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/13/2024] [Indexed: 09/04/2024]  Open
29
Ignatiadis M, Poulakaki F, Spanic T, Brain E, Lacombe D, Sonke GS, Vincent-Salomon A, Van Duijnhoven F, Meattini I, Kaidar-Person O, Aftimos P, Lecouvet F, Cardoso F, Retèl VP, Cameron D. EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe. Eur J Cancer 2024;207:114156. [PMID: 38861756 DOI: 10.1016/j.ejca.2024.114156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2024] [Revised: 05/29/2024] [Accepted: 05/30/2024] [Indexed: 06/13/2024]
30
Bradbury M, Savard MF, Stober C, Clemons L, Clemons M, Hilton J, Pond G, Vandermeer L, McGee SF. Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey. Breast Cancer Res Treat 2024;206:473-481. [PMID: 38664288 DOI: 10.1007/s10549-024-07302-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Accepted: 02/21/2024] [Indexed: 06/27/2024]
31
Mittal A, Moore S, Navani V, Jiang DM, Stewart DJ, Liu G, Wheatley-Price P. What Is Ailing Oncology Clinical Trials? Can We Fix Them? Curr Oncol 2024;31:3738-3751. [PMID: 39057147 PMCID: PMC11276279 DOI: 10.3390/curroncol31070275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2024] [Revised: 06/21/2024] [Accepted: 06/24/2024] [Indexed: 07/28/2024]  Open
32
Wilson BE, Eisenhauer EA, Booth CM. Study Participants, Future Patients, and Outcomes That Matter in Cancer Clinical Trials. JAMA 2024;331:2081-2083. [PMID: 38767591 DOI: 10.1001/jama.2024.1281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/22/2024]
33
Naci H, Zhang Y, Woloshin S, Guan X, Xu Z, Wagner AK. Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis. Lancet Oncol 2024;25:760-769. [PMID: 38754451 DOI: 10.1016/s1470-2045(24)00152-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Revised: 02/24/2024] [Accepted: 03/14/2024] [Indexed: 05/18/2024]
34
Turner JH. Theranostic Innovation by Humane N-of-One Cancer Care in Real-World Patients. Cancer Biother Radiopharm 2024;39:323-329. [PMID: 38324047 DOI: 10.1089/cbr.2023.0198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2024]  Open
35
Dee EC, Chino F, Johnson MN. Disparities in Cardio-Oncology Care Among Patients With Prostate Cancer. JACC CardioOncol 2024;6:402-404. [PMID: 38983374 PMCID: PMC11229540 DOI: 10.1016/j.jaccao.2024.05.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/11/2024]  Open
36
Wilson BE, Sengar M, Tregear M, van der Graaf WTA, Luca Battisti NM, Csaba DL, Soto-Perez-de-Celis E, Gyawali B, Booth CM. Common Sense Oncology: Equity, Value, and Outcomes That Matter. Am Soc Clin Oncol Educ Book 2024;44:e100039. [PMID: 38788178 DOI: 10.1200/edbk_100039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2024]
37
Roncolato F, King MT, O'Connell RL, Lee YC, Joly F, Hilpert F, Lanceley A, Yoshida Y, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Ledermann JA, Berton D, Sehouli J, Kaminsky MC, Stockler MR, Friedlander M. Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer. Gynecol Oncol 2024;185:128-137. [PMID: 38412736 DOI: 10.1016/j.ygyno.2024.02.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Revised: 02/15/2024] [Accepted: 02/18/2024] [Indexed: 02/29/2024]
38
Roets E, van der Graaf W, van Riet BHG, Haas RL, Younger E, Sparano F, Wilson R, van der Mierden S, Steeghs N, Efficace F, Husson O. Patient-reported outcomes in randomized clinical trials of systemic therapy for advanced soft tissue sarcomas in adults: A systematic review. Crit Rev Oncol Hematol 2024;197:104345. [PMID: 38582227 DOI: 10.1016/j.critrevonc.2024.104345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2024] [Revised: 03/29/2024] [Accepted: 04/01/2024] [Indexed: 04/08/2024]  Open
39
Stewart DJ, Bradford JP, Sehdev S, Ramsay T, Navani V, Rawson NSB, Jiang DM, Gotfrit J, Wheatley-Price P, Liu G, Kaplan A, Spadafora S, Goodman SG, Auer RAC, Batist G. New Anticancer Drugs: Reliably Assessing "Value" While Addressing High Prices. Curr Oncol 2024;31:2453-2480. [PMID: 38785465 PMCID: PMC11119944 DOI: 10.3390/curroncol31050184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2024] [Revised: 04/24/2024] [Accepted: 04/26/2024] [Indexed: 05/25/2024]  Open
40
van Nassau SCMW, Bol GM, van der Baan FH, Roodhart JML, Vink GR, Punt CJA, May AM, Koopman M, Derksen JWG. Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand? Curr Treat Options Oncol 2024;25:405-426. [PMID: 38367182 PMCID: PMC10997699 DOI: 10.1007/s11864-024-01186-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/17/2024] [Indexed: 02/19/2024]
41
Sanford NN, Lievens Y, Aggarwal A, Hanna TP, Dawson LA, White J, Gyawali B, Booth C, de Moraes FY. Common Sense (Radiation) Oncology: Redefining targets in radiotherapy. Radiother Oncol 2024;193:110118. [PMID: 38316192 DOI: 10.1016/j.radonc.2024.110118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Revised: 01/24/2024] [Accepted: 01/28/2024] [Indexed: 02/07/2024]
42
Tang C, Msaouel P. Charting the Path to Systemic Therapy De-escalation-Oligometastatic Kidney Cancer as a Paradigm. JAMA Oncol 2024:2815668. [PMID: 38451536 DOI: 10.1001/jamaoncol.2023.7266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/08/2024]
43
El Bairi K, Trapani D, Teuwen LA, Rodrigues B, Mutebi M. Integrity matters in oncology: AORTIC takes a stand against research misconduct. BJC REPORTS 2024;2:11. [PMID: 39516262 PMCID: PMC11523996 DOI: 10.1038/s44276-023-00032-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Revised: 12/19/2023] [Accepted: 12/20/2023] [Indexed: 11/16/2024]
44
Ghose A, Stanway S, Sirohi B, Mutebi M, Adomah S. Advanced Breast Cancer Care: The Current Situation and Global Disparities. Semin Oncol Nurs 2024;40:151551. [PMID: 38065813 DOI: 10.1016/j.soncn.2023.151551] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Revised: 10/31/2023] [Accepted: 11/01/2023] [Indexed: 02/12/2024]
45
Gyawali B, Booth CM. Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients. Lancet Oncol 2024;25:167-170. [PMID: 38301687 DOI: 10.1016/s1470-2045(23)00516-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2023] [Revised: 09/26/2023] [Accepted: 09/29/2023] [Indexed: 02/03/2024]
46
Leary A, Besse B, André F. The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology. Lancet 2024;403:406-408. [PMID: 38081195 DOI: 10.1016/s0140-6736(23)02199-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Revised: 09/25/2023] [Accepted: 09/29/2023] [Indexed: 01/29/2024]
47
Bradbury M, Savard MF, Vandermeer L, Clemons L, Pond G, Hilton J, Clemons M, McGee S. Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective. Curr Oncol 2023;30:10477-10487. [PMID: 38132397 PMCID: PMC10742686 DOI: 10.3390/curroncol30120763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Revised: 12/07/2023] [Accepted: 12/12/2023] [Indexed: 12/23/2023]  Open
48
Hammad N, Ginsburg O. Investing in gender equality and equitable access improves outcomes. Lancet Oncol 2023;24:1302-1304. [PMID: 37924820 DOI: 10.1016/s1470-2045(23)00521-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Accepted: 10/04/2023] [Indexed: 11/06/2023]
49
Landman A, Collingridge D. Global cancer surgery: a vital service to eliminate false economy. Lancet Oncol 2023;24:1296-1297. [PMID: 37924823 DOI: 10.1016/s1470-2045(23)00533-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2023]
50
Smith S, Kao S. PEMMELA: a promising regimen at the expense of toxicity. Lancet Oncol 2023;24:1161-1162. [PMID: 37844596 DOI: 10.1016/s1470-2045(23)00512-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2023] [Accepted: 09/26/2023] [Indexed: 10/18/2023]
PrevPage 1 of 2 12Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA